Analyst Ratings for Rocket Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Rocket Pharmaceuticals (NASDAQ:RCKT) has received mostly bullish ratings from analysts in the last quarter, with 7 out of 8 ratings being bullish and 1 somewhat bullish. The average price target for the stock is $54.38, significantly higher than its current price of $20.24, implying a potential upside. The average price target has increased by 0.7% over the past month.
November 07, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rocket Pharmaceuticals has received mostly bullish ratings from analysts, with a significant potential upside indicated by the average price target of $54.38 compared to its current price of $20.24.
The bullish ratings from analysts and the significant potential upside indicated by the average price target suggest a positive short-term impact on Rocket Pharmaceuticals' stock. The increase in the average price target over the past month also indicates growing confidence among analysts in the stock's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100